Ipsc Derived Lrrk2 G2019S Dopaminergic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Description: Induced pluripotent stem cell (iPSC)-derived dopaminergic neurons carrying the LRRK2 G2019S mutation, the most common genetic cause of familial Parkinson's disease.
The G2019S mutation in LRRK2 (Leucine-Rich Repeat Kinase 2) is the most frequent known genetic cause of Parkinson's disease, accounting for 5-10% of familial cases and 1-3% of sporadic cases. iPSC-derived neurons provide a human disease model to study mechanisms and test therapies.
- Position: Chromosome 12, exon 41
- Change: c.6055G>A, p.Gly2019Ser
- Inheritance: Autosomal dominant
- Penetrance: Age-dependent, 25-100%
- Kinase activity: 2-3 fold increase
- Autophosphorylation: Enhanced
- Substrate phosphorylation: Rab proteins
- Cellular localization: Altered
- Pluripotent stem cells: Patient iPSCs
- Neural rosettes: Neuroectoderm
- Floor plate induction: FOXA2, LMX1A
- Midbrain patterning: Otx2, Engrailed-1
- Dopaminergic differentiation: TH+, FOXA2+
- Maturation: 60-90 days
- Markers: TH, FOXA2, LMX1A, NURR1, PITX3
- Electrophysiology: Action potentials
- Dopamine release: Functional assays
- Increased kinase activity: LRRK2 hyperactivation
- Altered morphology: Reduced neurite length
- Mitochondrial dysfunction: Complex I deficiency
- Autophagy impairment: Lysosomal defects
- Oxidative stress: ROS accumulation
- Phospho-Rab10: Elevated
- Phospho-T73 Rab8: Increased
- p62/SQSTM1: Accumulation
- TFEB: Impaired nuclear translocation
- Mechanism studies: LRRK2 toxicity pathways
- Drug screening: Kinase inhibitors
- Biomarker discovery: Phospho-Rab10
- LRRK2 inhibitors: DNL151, BIIB122
- Target validation: Genetic rescue studies
- Personalized medicine: Patient-specific models
The study of Ipsc Derived Lrrk2 G2019S Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- iPSC models of LRRK2-PD (2016)
- LRRK2 G2019S pathophysiology (2019)
- LRRK2 inhibitor clinical trials (2021)
- Phospho-Rab10 as biomarker (2020)